Wikipedia -WSS

Wikipedia

author：fashion 2025-09-30 11:06:58 - browse：6

Stock exchange — Drew Angerer/Getty Images

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

hotspot

WSS

Beware the threat of staffing cuts at the CDC

Roivant's CEO is a star, but biotech's black hole persists

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Merck, Daiichi strike cancer drug pact worth up to $22 billion

ADCs take center stage as promising cancer treatments

Hilary expected to bring catastrophic, life

entertainment

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

At least 13 dead in Texas as scorching temps continue

STAT Readout Newsletter: Biotech news today

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

STAT Summit: The economic case for universal basic health care

Sports medicine is finally prioritizing gender equality

Lung cancer is America's deadliest cancer. Yet so few get screened

Trump demands the U.S. pay no more for drugs than other countries … again

Is there really a nursing shortage in the U.S.?

In Memoriam: Notable people who died in 2023

Roche acquires Telavant from Roivant, adding experimental IBD treatment

focus

Beware the threat of staffing cuts at the CDC

STAT Summit: How researchers deal with rejection

J&J lung cancer data amount to new salvo against AstraZeneca

Patient advocates sound warning on FDA proposal on salt intake

Baltimore teen accused of firing into crowd during block party mass shooting

Why a market frenzy over new weight loss drugs defies logic

hotspot

hotspot

hotspot

focus